By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Syndax Pharmaceuticals Inc. 

400 Totten Pond Road
Suite 110
Waltham  Massachusetts  02451  U.S.A.
Phone: 781-419-1400 Fax: 781-419-1420


SEARCH JOBS



Segment
Start Up





Company News
Allan L. Shaw Joins Syndax As Chief Financial Officer 1/20/2016 6:24:13 AM
Merck KGaA (MKGAF.PK), Darmstadt, Germany, Pfizer (PFE) And Syndax Announce Collaboration To Evaluate Combination Of Avelumab And Entinostat In Ovarian Cancer 1/4/2016 7:46:12 AM
Syndax Announces Multiple Data Presentations On Entinostat At Upcoming San Antonio Breast Cancer Symposium 12/3/2015 7:35:35 AM
Syndax And Merck & Co. (MRK) Announce First Patients Dosed In Phase 1b/2 Clinical Trial Of Entinostat And KEYTRUDA 9/28/2015 7:58:57 AM
Syndax To Present At Two Upcoming Scientific Conferences 9/16/2015 12:04:52 PM
Michael Meyers, M.D., Ph.D., Joins Syndax As SVP And Chief Development Officer 9/1/2015 6:19:36 AM
Joining the Anti-PD-L1 Cancer Drug Market, Syndax Inks Deal With Genentech (RHHBY), Closes on $80 Million Series C Round 8/26/2015 6:34:54 AM
Massachusetts' Syndax Banks $80 Million Series C 8/24/2015 6:27:28 AM
Ex-AstraZeneca PLC (AZN) CMO Takes Helm at Tiny Syndax 6/15/2015 6:17:22 AM
Syndax Pharmaceuticals Inc. And Merck & Co. (MRK) To Collaborate On Immuno-Oncology Study Evaluating Entinostat In Combination With KEYTRUDA (Pembrolizumab) In Lung Cancer And Melanoma 3/31/2015 11:28:27 AM
1234567
//-->